First Tracks Biotherapeutics
Clinical-stage biotech developing antibody therapies that modulate immune pathways to treat autoimmune and inflammatory diseases.
Pipeline: CD122 antagonist for celiac disease and eosinophilic esophagitis; pathogenic T‑cell depleter for rheumatoid arthritis; BDCA2 modulator.
Employees
loading...
Funding Status
loading...
Established
loading...
Total Funding
loading...
ARR
loading...
Insights
Loading Insights...
Loading Insight content to display...
Loading Insights...
Loading Insight content to display...
Founders
loading...
Notable Customers
loading...
Funding
Workforce
Functional Distribution
N/A
Open Positions
N/A
Diversity
N/A
